SCHEMBL15906204

SCHEMBL15906204

C[C@H]1CC[C@H](NC(=O)C2(N)CCC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.50
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ADRA2A P08913 1/20 0.39
RAB9A P51151 6/20 0.38
NPC1 O15118 5/20 0.38
PRNP P04156 1/20 0.38
TAS1R3 Q7RTX0 2/20 0.38
TAS1R1 Q7RTX1 2/20 0.38
TAS1R2 Q8TE23 2/20 0.38
MAPK1 P28482 2/20 0.38
HPGD P15428 2/20 0.38
GAA P10253 1/20 0.35
GFER P55789 1/20 0.35
F2 P00734 1/20 0.35
PLG P00747 1/20 0.35
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35
ST14 Q9Y5Y6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15906234 0.96 EPHX1 (0.50) EPHX1ALDH1A1SMN1; SMN2ADRA2ARAB9A
SCHEMBL15906215 0.93 EPHX1 (0.48) EPHX1ALDH1A1SMN1; SMN2ADRA2ARAB9A
SCHEMBL23663375 0.82 EPHX2 (0.39) EPHX1ALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL14652103 0.81 OPRL1 (0.35) EPHX1ALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL11857733 0.81 EPHX1 (0.46) EPHX1ALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL29031342 0.79 EPHX1 (0.48) EPHX1ALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL14652101 0.78 MME (0.37) EPHX1ALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL14654900 0.77 EPHX1 (0.37) EPHX1SMN1; SMN2RAB9ANPC1HPGD
SCHEMBL25676341 0.76 EPHX1 (0.50) EPHX1ALDH1A1SMN1; SMN2ADRA2ARAB9A
SCHEMBL25019291 0.76 EPHX1 (0.50) EPHX1ALDH1A1SMN1; SMN2ADRA2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791257-B2 Substituted pyrrolotriazines as protein kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-07-29 US disclosed